Revenue
No reported data
Drugs Made In America Acquisition II Corp. (DMII)
Price—Loading quote
Net income
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | |
|---|---|
| Operating expenses | $488,385 |
| Operating income | −$488,385 |
| Net income | $4.2M |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 26, 2025Form 4 | Stockwell LynnCEO and Exe. Chair of Board | SellOrdinary shares · indirect | 7.97M | — | — | 6.71M |
| Sep 26, 2025Form 4 | Stockwell LynnCEO and Exe. Chair of Board | BuyOrdinary shares · indirect | 700.0K | — | — | 15.07M |
| Sep 26, 2025Form 4 | Stockwell LynnCEO and Exe. Chair of Board | BuyRights to receive ordinary shares · derivative · indirect | 700.0K | — | — | 700.0K |
| Sep 26, 2025Form 4 | Drugs Made In America Acquisition II LLCTenPercentOwner | SellOrdinary shares | 7.97M | — | — | 6.71M |
| Sep 26, 2025Form 4 | Drugs Made In America Acquisition II LLCTenPercentOwner | BuyOrdinary shares | 700.0K | — | — | 15.07M |